Revised forecast
Fiscal year ending December 2026 · Full yearPrevious forecast published 9 February 2026The bar length represents the relative magnitude of change, based on the item that changed the most in this document. The percentage change shown by the dotted line is calculated from the two reported figures because the company did not provide the rate.
As the discontinuation of the rocatinlimab clinical trial program decided on 3 March 2026 means that the associated selling, general and administrative expenses and research and development expenses are no longer expected to be incurred, core operating profit is expected to exceed the previous forecast. Meanwhile, other expenses are expected to increase due to the recognition of closing costs and other items, and profit for the period is expected to remain unchanged from the previous forecast.
An impairment loss and reversal of impairment loss (gain) of ¥4,949 million were recorded in the first quarter. The reasons for revising the full-year forecast refer to closing costs and other items associated with the discontinuation of the rocatinlimab clinical trial program, but the amount was Not disclosed.
| Item | Details |
|---|---|
| Net Sales | ¥520,000 million → ¥520,000 million |
| Operating profit | ¥100,000 million → ¥130,000 million（30.0％） |
| Profit attributable to owners of the parent | ¥75,000 million → ¥75,000 million |
| Net income per share | 143.27 yen → 143.27 yen |
| Fiscal Period Covered | Fiscal year ending December 2026 |
| Period Covered | Full year |
| Publication date of previous forecast | 9 February 2026 |
| Previous-period results | Revenue ¥496,826 million / Core operating profit ¥109,838 million / Income before taxes ¥87,221 million / Profit for the period ¥67,040 million / Basic earnings per share ¥128.07 / Core profit for the period ¥84,424 million / Basic core profit per share ¥161.28 |
| Reason for the revision | As the discontinuation of the rocatinlimab clinical trial program decided on 3 March 2026 means that the associated selling, general and administrative expenses and research and development expenses are no longer expected to be incurred, core operating profit is expected to exceed the previous forecast. Meanwhile, other expenses are expected to increase due to the recognition of closing costs and other items, and profit for the period is expected to remain unchanged from the previous forecast. |
| Details and amount of extraordinary loss | An impairment loss and reversal of impairment loss (gain) of ¥4,949 million were recorded in the first quarter. The reasons for revising the full-year forecast refer to closing costs and other items associated with the discontinuation of the rocatinlimab clinical trial program, but the amount was Not disclosed. |
| Dividend forecast revision | No revision |
| Consolidated / non-consolidated | Consolidated |
Items this document does not state (1)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The discontinuation of the rocatinlimab clinical trial program means that the associated selling, general and administrative expenses and research and development expenses are no longer expected to be incurred, which is expected to boost core operating profit. Meanwhile, other expenses are expected to increase due to the recognition of closing costs and other items, so profit for the period is expected to remain unchanged from the previous forecast.